The historical rank and industry rank for BridgeBio Pharma's Price-to-Tangible-Book or its related term are showing as below:
During the past 7 years, BridgeBio Pharma's highest Price to Tangible Book Ratio was 150.98. The lowest was 5.48. And the median was 12.81.
BBIO's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.835 * Ranked among companies with meaningful Price-to-Tangible-Book only.
BridgeBio Pharma Price-to-Tangible-Book Historical Data
The historical data trend for BridgeBio Pharma's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BridgeBio Pharma's Price-to-Tangible-Book
For the Biotechnology subindustry, BridgeBio Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
BridgeBio Pharma Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of BridgeBio Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
BridgeBio Pharma (BridgeBio Pharma) Business Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BBIO has been successfully added to your 